NAD+ IV Dosing Information
No Established Medical Dosing Guidelines Exist
There are no FDA-approved dosing protocols, clinical practice guidelines, or high-quality evidence establishing a recommended starting dose for intravenous NAD+ administration. The available evidence consists only of a single retrospective observational study from a commercial wellness setting and a homeopathic product label, neither of which provides medically validated dosing recommendations.
Critical Evidence Gaps
What the Evidence Shows:
Commercial Practice Data Only: One retrospective study 1 examined 500 mg NAD+ IV administered over four consecutive days in a wellness clinic setting. This dose resulted in:
- Moderate to severe gastrointestinal symptoms
- Increased heart rate and chest pressure during infusions
- Average infusion time of 97 minutes (significantly longer than alternative precursors)
- All symptoms resolved upon infusion completion
No FDA Approval: The only drug label identified 2 is for a homeopathic oral preparation, not an FDA-approved intravenous formulation. This provides no guidance for IV dosing.
Lack of Clinical Validation: The research literature 3 emphasizes that intravenous NAD+ administration "is less well characterized and lacks robust clinical validation." NAD+ responses are nonlinear and influenced by multiple factors including dose, age, metabolic state, and route of administration.
Clinical Reality and Safety Concerns
Why This Matters:
Without established guidelines, any IV NAD+ administration represents off-label use with unknown safety profiles. The commercial study 1 demonstrated significant tolerability issues even at 500 mg, suggesting this may not represent an optimal starting dose despite its use in wellness settings.
Key Safety Considerations:
- Symptom Burden: The 500 mg dose produced moderate-to-severe symptoms requiring extended infusion times
- No Dose-Finding Studies: There are no systematic studies establishing minimum effective doses or maximum tolerated doses
- Unknown Long-term Safety: The longest follow-up in available data is 30 days 1
- No Renal/Hepatic Dosing: Despite your specification of normal organ function, there are no established dosing modifications for any patient population
What Cannot Be Recommended
Given the absence of:
- FDA-approved IV NAD+ products
- Clinical practice guidelines from any medical society
- Randomized controlled trials establishing efficacy or safety
- Pharmacokinetic studies defining appropriate dosing ranges
I cannot provide a medically validated starting dose recommendation. The 500 mg dose used in commercial settings 1 represents observational practice data only, not evidence-based medicine.
Alternative Consideration:
If NAD+ augmentation is the therapeutic goal, oral precursors (nicotinamide riboside or nicotinamide mononucleotide) have more established safety profiles and demonstrated ability to increase circulating NAD+ levels 3, though their clinical benefits remain variable and context-dependent.